glp-1 agonists tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis Tirzepatide, a dual GIP/GLP-1 receptor

Pendulum Glucose Control

This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota

Obesity and type 2 diabetes remain critical global health challenges, with rising prevalence demanding innovative treatment approaches

Safe, drug-free, non-GMO, USA-made

Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality

Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity